Pazopanib, Another Drug in the Arsenal of Weapons Against Renal Cell Cancer – ESMO 2012

Pazopanib, another drug in the arsenal of weapons against renal cell cancer – ESMO 2012 – Cora Sternberg describes an interesting phase III study confirming the positive results for a new drug in RCC treatment. This study was presented during ESMO 2012, the Congress of the European Society for Medical Oncology. Read all the news about the latest in cancer and oncology from the Congress here www.esmo.org The opinion expressed in this interview reflects that of the interviewee and does not necessarily express the official ESMO point of view.

Amgen's Heart Drug Lowers Patient Cholesterol in Study

Filed under: drug treatment news 2012

Amgen's Heart Drug Lowers Patient Cholesterol in Study. By Ryan Flinn – 2012-11-06T15:46:00Z … Some of the patients were also taking Merck & Co.'s cholesterol treatment Zetia. Amgen's drug is one of several that companies are developing to target the …
Read more on Bloomberg

Curis Reports Third Quarter 2012 Financial Results

Filed under: drug treatment news 2012

6, 2012 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the third quarter ended …
Read more on NASDAQ